CCL2 and neoplasm: Given that gefitinib, TAMs, and CCL2 are all interconnected with tumor vascularization processes (Singh et al., 2023; Dallavalasa et al., 2021; O'Connor and Heikenwalder, 2021), it is plausible that FMD influences gefitinib’s anti-angiogenic effect.